85. Osteogenic Osteosarcoma

  1. Clifford J. Rosen MD
  1. Jianning Tao,
  2. Yangjin Bae,
  3. Lisa L. Wang and
  4. Brendan Lee

Published Online: 19 JUL 2013

DOI: 10.1002/9781118453926.ch85

Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, Eighth Edition

Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, Eighth Edition

How to Cite

Tao, J., Bae, Y., Wang, L. L. and Lee, B. (2013) Osteogenic Osteosarcoma, in Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, Eighth Edition (ed C. J. Rosen), John Wiley & Sons, Inc., Ames, USA. doi: 10.1002/9781118453926.ch85

Publication History

  1. Published Online: 19 JUL 2013

ISBN Information

Print ISBN: 9781118453889

Online ISBN: 9781118453926

SEARCH

Keywords:

  • animal models;
  • biomarkers;
  • cancer stem cells (CSCs);
  • mutations;
  • osteogenic osteosarcoma

Summary

Recent reviews on studies of familial syndromes, specimens, and cell lines derived from human osteosarcoma patients describe the genetic factors and signaling pathways that may be involved in several key processes in the pathogenesis, including initiation, progression, invasion, and metastasis. This chapter updates the current understanding of osteogenic osteosarcoma biology and reviews these recent findings from animal models. Osteosarcoma premalignant cells that initially acquire a mutation in different stages of osteoblast differentiation may transform or evolve into cancer stem cells (CSCs) or tumor initiating cells (TICs) through accumulation of additional genetic mutations during the tumor progression. The current challenge in application of targeted agents lies in the identification of biomarkers predictive of response/resistance and matching them with the particular histologic response of individual patients, hopefully resulting in successful translation of biology into clinical benefit.